{"schema_version":"secwatch.filing_event.v1","accession":"0001599298-23-000009","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.770705+00:00","generated_at":"2026-06-20T17:51:12.615667+00:00","sec_items":["2.02","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Summit reports preliminary cash of at least $648M; shareholders authorize share increase and reverse split","bullets":["Preliminary unaudited cash, equivalents and escrow balance no less than $648M as of Dec 31, 2022.","Includes $300M upfront to Akeso held in escrow pending HSR clearance for ivonescimab license.","Stockholders approved increasing authorized shares from 350M to 1B and a reverse stock split (1:5 to 1:10), board discretion within one year.","Company to present at 41st J.P. Morgan Healthcare Conference on Jan 9, 2023, highlighting ivonescimab."],"urls":{"canonical":"https://secwatch.observer/filing/0001599298-23-000009","json":"https://secwatch.observer/filing/0001599298-23-000009.json","markdown":"https://secwatch.observer/filing/0001599298-23-000009.md","text":"https://secwatch.observer/filing/0001599298-23-000009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/smmt-20230106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:51:12.615667+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19319cdbfa7eeb255f57385e528d4a5101ae1aad","claim":"Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to increase authorized shares of common stock from 350,000,000 to 1,000,000,000 at the 2023-01-06 meeting.","evidence_excerpt":"Proposal 1 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to increase the number of authorizes shares of common stock 188,470,028 1,585,907 165,798 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-06"}],"fact_type":"shareholder_vote"},{"claim_id":"d3426158c68ae27d4b2f1564673e1dc2969576d1","claim":"Summit Therapeutics Inc. shareholders approved Amendment to Restated Certificate to effect a reverse stock split at a ratio in the range of 1-for-5 to 1-for-10 at the 2023-01-06 meeting.","evidence_excerpt":"Proposal 2 For Against Abstain Broker Amendment No. 2 to Restated Certificate of Incorporation to effect a reverse stock split of the outstanding common stock 186,585,821 3,607,721 28,191 —","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929823000009/0001599298-23-000009-index.htm","confidence":0.95,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-01-06"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}